Market revenue in 2022 | USD 127.2 million |
Market revenue in 2030 | USD 674.5 million |
Growth rate | 23.2% (CAGR from 2022 to 2030) |
Largest segment | Cell therapy |
Fastest growing segment | Gene Therapy |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Gene Therapy, Cell Therapy |
Key market players worldwide | Lonza Group Ltd, Bluebird bio Inc, Catalent Inc, Roche, Samsung BioLogics, Boehringer Ingelheim, Hitachi Ltd, Takara Bio Inc, Miltenyi Biotec, Thermo Fisher Scientific Inc, Novartis AG ADR, Merck KGaA, Wuxi AppTec Co Ltd |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy manufacturing market will help companies and investors design strategic landscapes.
Cell therapy was the largest segment with a revenue share of 67.77% in 2022. Horizon Databook has segmented the India cell and gene therapy manufacturing market based on gene therapy, cell therapy covering the revenue growth of each sub-segment from 2018 to 2030.
India is expected to witness lucrative growth in the cell and gene therapy manufacturing market. The Indian healthcare industry is witnessing growing demand for advanced therapeutic solutions, such as gene- and cell-based therapies, to treat life-threatening diseases.
Owing to this, the cell and gene therapy manufacturing market in India is expected to witness growth. In December 2019, the Indian Council of Medical Research (ICMR) issued national guidelines for developing and applying gene therapies in India.
This is expected to increase the number of clinical trials for gene therapies in the country by accelerating innovation and research in gene therapies. Such government policies are expected to boost market penetration for cell and gene therapy manufacturing in India.
Horizon Databook provides a detailed overview of country-level data and insights on the India cell and gene therapy manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into India cell and gene therapy manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account